A. Narayana

发表

Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.

S. Passik, Ronghua Yang, A. Narayana, 2014, Pain medicine.

Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.

S. Passik, A. Narayana, P. Fine, 2010, Pain medicine.

Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment

R. Griggs, A. Connolly, J. Kwon, 2017, World Journal of Pediatrics.

The National Breakthrough Pain Survey (NBTPS): assessment of quality-of-life, functioning, and productivity

A. Shillington, R. Portenoy, A. Narayana, 2011 .

Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis

A. Narayana, A. M. Rosen, H. Zimmermann, 2022, Neurology and Therapy.

Costs associated with breakthrough pain in cancer patients: findings from the national breakthrough pain survey

A. Shillington, J. Stephenson, R. Portenoy, 2013 .

Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis

A. Narayana, A. M. Rosen, H. Zimmermann, 2022, Neurology and Therapy.

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, N. Bellamy, 2010, PAIN®.

Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients

A. Narayana, S. Nalamachu, L. Janka, 2011, Current medical research and opinion.

National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes

A. Shillington, J. Stephenson, R. Portenoy, 2015, Pain.

Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.

L. Webster, Ronghua Yang, A. Narayana, 2013, Pain medicine.

Ambulatory blood pressure and coronary artery calcification in middle-aged and younger adults.

L. Bielak, P. Peyser, P. Sheedy, 2002, American journal of hypertension.

Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update

M. Benson, P. Dyck, M. Gertz, 2022, Journal of Neurology.

Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain

Ronghua Yang, A. Narayana, R. Malamut, 2015, Journal of pain research.

Elan: ziconotide review focused on off-label uses.

A. Narayana, 2005, The American journal of hospice & palliative care.

T622 FENTANYL BUCCAL TABLET VS IMMEDIATE-RELEASE OXYCODONE FOR THE MANAGEMENT OF BREAKTHROUGH PAIN IN OPIOID-TOLERANT PATIENTS WITH CHRONIC PAIN

M. Ashburn, G. Varrassi, A. Narayana, 2011 .

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, N. Bellamy, 2010, PAIN®.